Drug Trial Radar · NCT04060654
SUBLOCADE Rapid Initiation Extension Study
Last checked: Nov 20, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Oct 21, 2019
Primary completion
May 15, 2020
Study completion May 15, 2020
Sponsor
- Lead sponsor
- Indivior Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A single center, open-label SUBLOCADE treatment extension study in which up to 25 participants diagnosed with moderate to severe opioid use disorder (OUD) could be enrolled.
Conditions
- Opioid Use Disorder, Severe
- Opioid Use Disorder, Moderate
Interventions
SublocadeDrug
SUBLOCADE to be administered approximately every 4 weeks per local standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Emergent Adverse Event (TEAE) OccurrenceTime frame: From time of informed consent at Day 1 until EOT, assessed up until Day 141
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hassman Research Institute
Berlin, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.